---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Antidepressant optimization, switching, and combination"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Antidepressant optimization, switching, and combination. Topics: CANMAT guideline: response and remission after first and second antidepressant trials; CANMAT guideline: dose optimization, switching, and sequencing of adjunctive strategies; CANMAT guideline: tricyclic antidepressants, MAOIs, and adjunctive antidepressants; NICE guideline: options after no or limited response to antidepressant medication; 13 further topics. 17 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/antidepressant-optimization-switching-and-combination"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Antidepressant optimization, switching, and combination

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Antidepressant Optimization, Switching, and Combination

<a id="topic-2.2.2.1.1-1"></a>

### CANMAT guideline: response and remission after first and second antidepressant trials

> “In real-world populations, approximately half of patients with MDD achieve response (>50% reduction in symptom severity) after 8 weeks of antidepressant monotherapy, while about a third attain full symptom remission; only a quarter of nonremitters who receive a second pharmacological treatment will reach remission.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.1-2"></a>

### CANMAT guideline: dose optimization, switching, and sequencing of adjunctive strategies

> “Optimizing the antidepressant dose is an important first step.”
> “Higher than minimal therapeutic doses are more effective (to a plateau around the equivalent of 50 mg of fluoxetine) but less well-tolerated”
> “The evidence for the efficacy of switching antidepressants is inconsistent. Meta-analyses show that switching to another antidepressant is not superior to continuing the same one and there appears to be diminishing response rates for antidepressant monotherapy beyond the first switch.”
> “Moreover, RCTs directly comparing switching to adjunctive strategies have shown that adjunctive strategies have superior outcomes and often similar tolerability.”
> “Hence, while balancing individual risks, benefits, and patient preference, CANMAT recommends that adjunctive strategies be considered earlier in the treatment algorithm, after limited response to the first or second antidepressant trial”
> “Switching should be considered first when there is no response to the initial antidepressant or when the first medication has troublesome side effects. Adjunctive strategies should be considered first when there is a partial response to the initial antidepressant and there are minimal or no tolerability issues with the first medication.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.1-3"></a>

### CANMAT guideline: tricyclic antidepressants, MAOIs, and adjunctive antidepressants

> “Hence, TCAs and MAOIs should be considered as therapeutic options when first-line and second-line medication treatments are not effective, with patients monitored carefully for side effects and potential for drug interactions.”
> “Compared to serotonin-dopamine activity-modulating agents, antidepressants generally have a more favourable side effect profile when used as adjunctive treatment, but the evidence for efficacy is less robust.”
> “Adding mirtazapine/mianserin (antagonists of presynaptic α2-adrenoceptors) is superior to other combinations. Large RCTs have shown evidence for the effectiveness of adjunctive bupropion but the meta-analyses are inconclusive. Hence, these are recommended as second-line treatments for DTD.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.1-4"></a>

### NICE guideline: options after no or limited response to antidepressant medication

> “If a person's depression has had no or a limited response to treatment with antidepressant medication alone, and no obvious cause can be found and resolved, discuss further treatment options with the person and make a shared decision on how to proceed based on their clinical need and preferences.”
> “increasing the dose of the current medication (within the licensed dose range) if the medication is well tolerated; be aware that higher doses of antidepressants may not be more effective and can increase the frequency and severity of side effects; ensure follow-up and frequent monitoring of symptoms and side effects after dose increases.”
> “switching to another medication in the same class (for example, another SSRI)”
> “switching to a medication of a different class (for example, an SSRI, SNRI, or in secondary care a TCA or MAOI); take into account that:”
> “TCAs are dangerous in overdose, although lofepramine has the best safety profile”

Source: [NICE (2022)](https://www.nice.org.uk/guidance/ng222/chapter/Recommendations)

<a id="topic-2.2.2.1.1-5"></a>

### NICE guideline: combining antidepressants

> “If a person whose depression has had no response or a limited response to antidepressant medication does not want to try a psychological therapy, and instead wants to try a combination of medications, explain the possible increase in their side-effect burden.”
> “adding an additional antidepressant medication from a different class (for example, adding mirtazapine or trazodone to an SSRI)”
> “Be aware that some combinations of classes of antidepressants are potentially dangerous and should be avoided (for example, a SSRI, SNRI or TCA with a MAOI)”

Source: [NICE (2022)](https://www.nice.org.uk/guidance/ng222/chapter/Recommendations)

<a id="topic-2.2.2.1.1-6"></a>

### VA/DoD guideline: next steps after partial or no response to initial pharmacotherapy

> “For patients with MDD who have demonstrated partial or no response to an adequate trial of initial pharmacotherapy, we suggest (not rank ordered):”
> “Switching to another antidepressant (including TCAs, MAOIs, or those in Recommendation 12)”
> “Switching to psychotherapy”
> “Augmenting with a psychotherapy”
> “Augmenting with a second-generation antipsychotic”
> “(Weak for | Reviewed, Amended)”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.1-7"></a>

### VA/DoD guideline: evidence on dose escalation, switching, and antidepressant combinations

> “An SR by Braun et al. (2020) found no clinically relevant dose-effects gradients for SSRIs and that dropout rates increased with dose, primarily due to side effects.”
> “In general, monotherapy with first-line antidepressants (e.g., SSRIs, SNRIs, bupropion, mirtazapine) is preferable to combination treatment with two antidepressants because of the increased potential for drug-drug interactions, adverse effects, and lack of clinical benefit.”
> “An SR by Bschor et al. (2018) and an RCT by Tadic et al. (2016) found no difference in antidepressant efficacy, symptom response, remission, adverse effects, and functional status between switching and continuation of antidepressant treatment.”
> “An SR by Davies et al. (2019) found no difference in depressive symptoms, remission, adverse events, QoL, and functional status in patients who received mirtazapine augmentation versus placebo augmentation.”
> “There was insufficient evidence to recommend bupropion even though the risks associated with augmentation are considered lower than with SGA’s, and in clinical practice, bupropion is preferred over an SGA.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.1-8"></a>

### ACP guideline: second-line options after nonresponse to a second-generation antidepressant

> “ACP suggests one of the following options for patients in the acute phase of moderate to severe major depressive disorder who did not respond to initial treatment with an adequate dose of a second-generation antidepressant: • Switching to or augmenting with cognitive behavioral therapy (conditional recommendation; low-certainty evidence) • Switching to a different second-generation antidepressant or augmenting with a second pharmacologic treatment (see Clinical Considerations) (conditional recommendation; low-certainty evidence)”

Source: [Qaseem et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36689752/)

<a id="topic-2.2.2.1.1-9"></a>

### Switching after SSRI failure: remission and response with bupropion, sertraline, or venlafaxine

> “We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg.”
> “Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events.”
> “After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant.”

Source: [Rush et al. (2006a)](https://pubmed.ncbi.nlm.nih.gov/16554525/)

<a id="topic-2.2.2.1.1-10"></a>

### Augmentation after SSRI failure: bupropion or buspirone added to citalopram

> “We randomly assigned 565 adult outpatients who had nonpsychotic major depressive disorder without remission despite a mean of 11.9 weeks of citalopram therapy (mean final dose, 55 mg per day) to receive sustained-release bupropion (at a dose of up to 400 mg per day) as augmentation and 286 to receive buspirone (at a dose of up to 60 mg per day) as augmentation.”
> “The sustained-release bupropion group and the buspirone group had similar rates of HRSD-17 remission (29.7 percent and 30.1 percent, respectively), QIDS-SR-16 remission (39.0 percent and 32.9 percent), and QIDS-SR-16 response (31.8 percent and 26.9 percent).”
> “a lower dropout rate due to intolerance (12.5 percent vs. 20.6 percent, P<0.009).”

Source: [Trivedi et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16554526/)

<a id="topic-2.2.2.1.1-11"></a>

### Remission and relapse across four sequential treatment steps

> “The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively. The overall cumulative remission rate was 67%. Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase.”
> “When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected.”

Source: [Rush et al. (2006b)](https://pubmed.ncbi.nlm.nih.gov/17074942/)

<a id="topic-2.2.2.1.1-12"></a>

### Reanalysis of cumulative remission with the protocol-specified rating scale

> “In contrast to the STAR*D-reported 67% cumulative remission rate after up to four antidepressant treatment trials, the rate was 35.0% when using the protocol-stipulated HRSD and inclusion in data analysis criteria.”
> “Combining STAR*D’s HRSD-defined remissions with those from the non-stipulated measure increased its cumulative remission rate from 35.0% to 41.3%.”

Source: [Pigott et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373710/)

<a id="topic-2.2.2.1.1-13"></a>

### Fourth-step treatment: MAOI versus venlafaxine plus mirtazapine

> “Remission rates were not significantly different between the two treatment groups (6.9% for the tranylcypromine group and 13.7% for the venlafaxine plus mirtazapine group).”
> “Tranylcypromine was associated with significantly less symptom reduction and greater attrition due to intolerance.”

Source: [McGrath et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16946177/)

<a id="topic-2.2.2.1.1-14"></a>

### Switching to bupropion versus bupropion or aripiprazole augmentation in veterans

> “Remission rates at 12 weeks were 22.3% (n = 114) for the switch group, 26.9% (n = 136)for the augment-bupropion group, and 28.9% (n = 146) for the augment-aripiprazole group.”
> “The augment-aripiprazole group exceeded the switch group in remission (relative risk [RR], 1.30 [95% CI, 1.05-1.60]; P = .02), but other remission comparisons were not significant.”
> “Anxiety was more frequent in the 2 bupropion groups (24.3% in the switch group [n = 124] vs 16.6% in the augment-aripiprazole group [n = 84]; and 22.5% in augment-bupropion group [n = 114]).”

Source: [Mohamed et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5817471/)

<a id="topic-2.2.2.1.1-15"></a>

### Augmentation versus switching in adults aged 60 years or older

> “Remission occurred in 28.9% of patients in the aripiprazole-augmentation group, 28.2% in the bupropion-augmentation group, and 19.3% in the switch-to-bupropion group. The rate of falls was highest with bupropion augmentation.”
> “In step 1, approximately 70% of the patients were adherent to aripiprazole augmentation and bupropion augmentation, but approximately 40% were adherent to the use of bupropion alone.”

Source: [Lenze et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10568698/)

<a id="topic-2.2.2.1.1-16"></a>

### Combining antidepressants versus monotherapy: meta-analysis

> “Thirty-nine RCTs including 6751 patients were eligible. Combination treatment was statistically significantly associated with superior treatment outcomes relative to monotherapy (SMD = 0.31; 95% CI, 0.19-0.44). Combining a reuptake inhibitor with an antagonist of presynaptic α2-autoreceptors was superior to other combinations (SMD = 0.37; 95% CI, 0.19-0.55).”
> “Numbers of dropouts and dropouts due to adverse events did not differ between treatments. Studies were heterogeneous, and there was indication of publication bias”

Source: [Henssler et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8851370/)

<a id="topic-2.2.2.1.1-17"></a>

### Mirtazapine added to an SSRI or SNRI in treatment-resistant depression in primary care

> “Beck depression inventory II scores at 12 weeks were lower in the mirtazapine group after adjustment for baseline scores and minimisation or stratification variables, although the confidence interval included the null (mean (SD) scores at 12 weeks: 18.0 (12.3) in the mirtazapine group, 19.7 (12.4) in the placebo group; adjusted difference between means −1.83 (95% confidence interval −3.92 to 0.27); P=0.09). Adverse effects were more common in the mirtazapine group and were associated with the participants stopping the trial drug.”

Source: [Kessler et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6207929/)

Additional sources: [American Psychiatric Association (2010)](https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf); [Qaseem et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41802255/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
